Navigation Links
PDL BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Provides First Quarter 2010 Revenue Guidance
Date:3/2/2010

ceives a flat three percent royalty as compared to the tiered royalty that it receives from Genentech for product sales that are either manufactured or sold in the United States.  As a percent of total Herceptin sales, ex-U.S. manufactured and sold Herceptin increased to 43 percent from 16 percent for the same period in the prior year. Ex-U.S. manufactured and sold Avastin sales represented five percent of total Avastin sales. This is the first quarter in which PDL has received royalties on sales of ex-U.S. manufactured and sold Avastin.

Reported sales of Lucentis increased 64 percent when compared to the same period for the prior year.  Ex-U.S. sales of Lucentis, which is approved in more than 80 countries worldwide, increased 88 percent when compared to the same period for the prior year and represented 57 percent of total global sales.

Reported sales of Tysabri increased 32 percent when compared to the same period for the prior year.  Ex-U.S. sales of Tysabri increased 42 percent when compared to the same period for the prior year, and represented 53 percent of total global sales.   Elan recently reported a 30 percent increase in the worldwide Tysabri patient population at the end of December 2009 as compared with December 2008.

'/>"/>
SOURCE PDL BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. ClearTrial Launches New Service to Bring Speed and Accuracy in Clinical Trial Planning Within Reach of Smaller Biopharma Companies
2. Indiana Biopharmaceutical Service Providers Maintain Steady Growth Despite Industry Challenges
3. SynCo Bio Partners Signs New Manufacturing Agreements to Supply the US Market; Securing its Position as a Market Leader in Microbial Biopharmaceutical Contract Production
4. ClearTrial to Demonstrate Dramatic Gains in Clinical Outsourcing Efficiency Achieved by Biopharmaceutical Companies at European Outsourcing Event
5. Sinobiopharma Announces Second Quarter 2010 Financial Results
6. Microbix And Therapure Biopharma Form Partnership To Expand Water-Based Supplies To The Pharma Industry
7. YM BioSciences Inc. and Therapure Biopharma Inc. Announce Contract
8. Array BioPharma and Amgen Partner in Type 2 Diabetes
9. PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million
10. PDL BioPharma Announces Ex-Dividend Date of November 27 for Special Dividend
11. PDL BioPharma Announces Special Dividend Payment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... Ill. , ROCHESTER, Minn. ... June 1, 2015 Baxter Ventures, the venture ... the Mayo Clinic and Velocity Pharmaceutical Development, LLC ("VPD") ... Vitesse is a unique collaboration model initiated by Baxter ... protein-based therapeutics in the areas of immunology, hematology, and ...
(Date:6/1/2015)... , June 1, 2015 /CNW/ - Resverlogix Corp. (TSX: ... RVX-208 was presented at the ERA-EDTA Congress in ... "Effects of RVX-208, a First-in-Class Epigenetic BET-Inhibitor, on Key ... and Chronic Kidney Disease (CKD); a Post-hoc Analysis of ... Dr. Kam Kalantar-Zadeh , Professor ...
(Date:6/1/2015)... June 1, 2015   Epic Sciences, Inc. , ... and offerings to personalize and advance the treatment and ... the available credit under its existing credit facility with ... increases the available capacity of the facility from $5 ... by 27 months to April 1, 2019.  The availability ...
(Date:6/1/2015)... 29, 2015 Research and Markets ... of the "2015 Strategies in European ... their offering. This new 273-page ... diagnostic market, including emerging tests, technologies, instrumentation, ... of leading suppliers. Companies Mentioned: ...
Breaking Biology Technology:Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 2Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 3Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 4Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 5Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 2Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 3Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 4Epic Sciences Expands Silicon Valley Bank Credit Facility 2Epic Sciences Expands Silicon Valley Bank Credit Facility 3
... Researchers have completed the first thorough, system-level assessment ... of microbes known as Shewanella. Microbes belonging to ... and cleaning up contaminated areas in the environment. ... Institute of Technology, Michigan State University and the ...
... ... , ... The Honolulu-based Pacific Health Research Institute (PHRI) has received $2.8 million in research funding ... a major lung cancer screening study in Hawaii, for two more years. , , , ...
... , , BOTHELL, Wash., ... a leading developer, manufacturer, and marketer of biopreservation tools for ... BloodStor biopreservation media product platform. The product family includes ... as well as other variants for peripheral blood derived stem ...
Cached Biology Technology:Hidden diversity in key environmental cleanup microbes found by systems biology assessment 2Hidden diversity in key environmental cleanup microbes found by systems biology assessment 3Pacific Health Research Institute Awarded $2.8 Million in Research Funding 2Pacific Health Research Institute Awarded $2.8 Million in Research Funding 3BloodStor(TM) Stem Cell Biopreservation Media Platform Launched by BioLife Solutions 2BloodStor(TM) Stem Cell Biopreservation Media Platform Launched by BioLife Solutions 3
(Date:5/21/2015)... , May 21, 2015 The Sync ... of music for health, today announced a collaborative partnership ... The partnership will center on collaboration on original research, ... first step in the collaboration, The Sync Project and ... "Music as Medicine" in the 2015-2016 academic year.  ...
(Date:5/19/2015)... NEW YORK , May 19, 2015  Technology ... resources both internally and in the cloud. Passwords and ... the use of OTP and standards-based specifications such as ... that the outmoded use of passwords presents for BYOD, ... needs a unified biometric identity protocol. ...
(Date:5/14/2015)... , May 14, 2015  Verificient Technologies, ... verification and online remote proctoring, announced a ... (SaaS) company and creator of the Canvas ... the two companies will benefit from the ... As a fully integrated multifactor ...
Breaking Biology News(10 mins):The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2
... discovered that iron-containing nanoparticles being tested for use in ... and interfere with the formation of their signal-transmitting extensions. ... and most life forms and iron oxide nanoparticles were ... professor of materials science at UCSD and senior author ...
... box glowing with fluorescent light, Stacie Grassano pulls out a tube. ... up to her face. Inside, a tree branch is speckled with ... Scott Costa. , Costa brings the branch close to his eye. ... success story." , For some, a fungus success story means ...
... announced that it has added high-density genotyping on ... list of services. Stan Nelson, the principal investigator ... for its user-base of ~10,000 investigators across the ... of the scientific community." , The Consortium ...
Cached Biology News:Widely used iron nanoparticles exhibit toxic effects on neuronal cells 2Widely used iron nanoparticles exhibit toxic effects on neuronal cells 3Fungal factories may save hemlock forests 2Fungal factories may save hemlock forests 3NIH neuroscience microarray consortium launches high-throughput genotyping services 2
Kanamycin is used for selection of resistant bacteria. C18H36N4O11xH2SO4. Contains 10 mg/ml kanamycin (base) utilizing kanamycin sulfate in 0.85% saline....
Request Info...
...
... Agarose-HR High Resolution - ... from 50 to 1000 ... for sizing PCR fragments, ... by restriction enzyme digestion, ...
Biology Products: